Efgartigimod
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists.
Target
FcRn
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Generalized Myasthenia Gravis (MG)
- gMG is a rare, chronic disorder where IgG antibodies damage the junction between nerves and muscles causing muscle weakness throughout the body
- IV efgartigimod
Primary Immune Thrombocytopenia (ITP)
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
- SC efgartigimod (enabled with Halozyme's ENHANZE® drug delivery technology)
Pemphigus Vulgaris (PV)
- PV is a rare, chronic and severe skin disorder where antibodies damage the connections within the skin and cause patients to develop blisters in the skin and other body surfaces, including in the mouth, nose and eyes
- IV efgartigimod
Clinical trials
argenx is running clinical trials of efgartigimod, in development for a range of severe autoimmune diseases. For more info on clinical trials with efgartigimod, please click the link below.
Proposed
Mechanism
of Action
